Buy Triquilar dragee 21 pcs
  • Buy Triquilar dragee 21 pcs

Ethinyl estradiol, Levonorgestrel

Bayer Pharma AG
1288 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Triquilar is a low-dose, three-phase oral combined estrogen-progestin contraceptive drug. Trikvilar contraceptive effect is implemented through three complementary mechanisms:
Suppression of ovulation at the level of the hypothalamic-pituitary regulation.
Changes in the properties of cervical secretions, as a result of which it becomes impermeable to sperm.
Changes in the endometrium, which makes implantation of a fertilized egg impossible.
In women taking combined oral contraceptives, the menstrual cycle becomes more regular, painful menstruation is less common, the intensity of bleeding decreases, resulting in a reduced risk of iron deficiency anemia.


Contraception (prevention of unwanted pregnancy).


Active substances: levonorgestrel, ethinyl estradiol;

Excipients: calcium carbonate, iron oxide pigment red, iron oxide pigment yellow, glycerol 85%, lactose monohydrate, magnesium stearate, corn starch, montan glycolic wax, macrogol 6000, povidone 25 000, povidone 700 000, sucrose, talc, titanium dioxide.

Ethinyl estradiol, Levonorgestrel is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Triquilar Bayer Pharma AG Germany dragee
Microgynon® Bayer Pharma AG Germany dragee
ThreeRegol® Gedeon Richter Hungary pills
Rigevidon Gedeon Richter Hungary pills
Rigevidon 21 + 7 Gedeon Richter Hungary pills
Minisiston® Bayer Pharma AG Germany dragee

No customer reviews for the moment.

Write your review

Write your review

Ethinyl estradiol, Levonorgestrel

Dosage and Administration

For oral use. pills should be taken in the order indicated on the packaging (blister), every day at about the same time, with a small amount of water. Take one tablet per day continuously for 21 days. Taking the pills from the next pack begins after a 7-day break in taking the pills, during which withdrawal bleeding usually occurs. Menstrual-like bleeding usually starts on the 2nd or 3rd day after taking the last pill and may not end before taking the pills from a new pack.

How to start taking the drug Trikvilar®

In the absence of taking any hormonal contraceptive drugs in the previous month. Trikvilar drug intake® Begins on the 1st day of the menstrual cycle (i.e., on the first day of the menstrual bleeding). It is allowed to start taking on the 2–5th day of the menstrual cycle, but in this case it is recommended to additionally use a barrier method of contraception during the first 7 days of taking the pills from the first package.

When switching from other COCs, vaginal ring or contraceptive patch. It is preferable to start taking the drug Trikvilar® the next day after taking the last active tablet from the previous package, but in no case later than the next day after the usual 7-day break (for drugs containing 21 pills) or after taking the last inactive tablet (for drugs containing 28 pills. packaged). Trikvilar drug intake® should begin on the day the vaginal ring or patch is removed, but no later than the day when a new ring is to be inserted or a new patch is pasted.

When switching from contraceptive preparations containing only gestagens («mini drank», injectable forms, implant), or with a progestogen-releasing intrauterine contraceptive (Mirena®). A woman can switch from a “mini-drink” to Triquilar®on any day (without a break), from the implant or intrauterine contraceptive with the progestogen - on the day of its removal, from the injection form - from the day when the next injection should be made. In all cases, you must use an additional barrier method of contraception during the first 7 days of taking pills.

After abortion in the first trimester of pregnancy. A woman can start taking the drug immediately. Subject to this condition, the woman does not need additional contraceptive protection.

After childbirth or abortion in the II trimester of pregnancy. It is recommended to start taking the drug on the 21-28th day after birth, if the woman is not breastfeeding, or after an abortion in the second trimester of pregnancy. If the reception is started later, you must use an additional barrier method of contraception during the first 7 days of taking the pills. However, during sexual intercourse, before starting the drug, Triquilar® pregnancy should be excluded or it is necessary to wait for the first menstruation.

Taking missed pills

If the delay in taking the drug was less than 12 hours, contraceptive protection is not reduced. A woman should take a pill as soon as possible, the next one is taken at the usual time.

If the delay in taking the pills is more than 12 hours, contraceptive protection can be reduced. The more pills are missed, and the closer the pass to the 7-day break in taking pills, the greater the likelihood of pregnancy. In this case, you can follow the following two basic rules:

- the drug should never be interrupted for more than 7 days;

- 7 days of continuous pills are required to achieve adequate suppression of the hypothalamic-pituitary-ovarian regulation.

Accordingly, the following recommendations can be given:

The first week of taking the drug. A woman should take the last missed pill; as soon as possible, as soon as he remembers (even if it means taking two pills at the same time).The next pill is taken at the usual time. Additionally, a barrier method of contraception (for example, a condom) should be used within the next 7 days. If sexual intercourse took place during the week before the pill is missed, the likelihood of pregnancy must be considered.

The second week of taking the drug. A woman should take the last missed pill as soon as she remembers (even if it means taking two pills at the same time). The next pill is taken at the usual time. Provided that the woman took the pills correctly within 7 days preceding the first missed pill, there is no need to use additional contraceptive measures. Otherwise, as well as skipping two or more pills, you must additionally use barrier methods of contraception (for example, a condom) for 7 days.

The third week of taking the drug. The risk of reducing the reliability is inevitable due to the upcoming break in taking pills. A woman should strictly adhere to one of the following two options. At the same time, if in the 7 days preceding the first missed pill, all the pills were taken correctly, there is no need to use additional contraceptive methods:

1. A woman should take the last missed pill as soon as possible, as soon as she remembers (even if it means taking two pills at the same time). The following pills are taken at the usual time, until the pills from the current packaging run out. Taking the pills from the next pack should start right away. Withdrawal bleeding is unlikely until the pills from the second package run out, but there may be bleeding of varying degrees of intensity (from lightening to breakthrough) while taking the pills.

2. A woman can also stop taking pills from the current pack. She should then take a break for 7 days, including the day she misses the pills, and then start taking the pills from the new pack. If a woman misses taking pills, and then during a break in reception she has no withdrawal bleeding, it is necessary to exclude pregnancy.

Recommendations for gastrointestinal disorders

If the woman had vomiting or diarrhea within 3-4 hours after taking the pills, the absorption may be incomplete and additional contraceptive measures should be taken. In these cases, you should focus on the recommendations when skipping pills.

Change the day of the onset of menstrual bleeding

In order to delay the onset of menstrual bleeding, a woman must continue taking the drug using the last 10 table. (numbered from 12 to 21) from another package of Triquilar®without interrupting reception. Thus, the cycle can be extended for up to 10 days until the end of the second package. While taking the drug from the second package, a woman may experience spotting or breakthrough uterine bleeding. Regular intake of the drug Triquilar® then resumes after the usual 7-day break in taking pills.

In order to postpone the day of the onset of menstrual bleeding to another day of the week, the woman should reduce the next break in the pill for the desired number of days. The shorter the interval, the higher the risk that she will not have withdrawal bleeding and there will be spotting or breakthrough bleeding while taking the pills from the second package (just as if she would like to delay the onset of menstrual bleeding).

Additional information for specific patient groups

Kids and teens

Drug Triquilar® contraindicated to establish ovulatory cycles.

Postmenopausal patients

Not applicable. Drug Triquilar® Prototype after menopause.

Patients with hepatic impairment

Drug Triquilar® contraindicated in women with severe liver disease, as long as the indicators of liver function do not come back to normal.

Patients with disorders of the kidneys. Drug Triquilar® not specifically studied in patients with impaired renal disease. The available data do not imply correction of the dosage regimen in such patients.

Adverse reactions

Soreness and tension of the mammary glands, an increase in the mammary glands, discharge from the mammary glands; spotting and breakthrough uterine bleeding; headache; migraine; libido change; decrease / change of mood; poor tolerance to contact lenses; visual impairment; nausea; vomiting; stomach ache; changes in vaginal secretion; skin rash; erythema nodosum; erythema multiforme; generalized itching; cholestatic jaundice; fluid retention; change in body weight; allergic reactions.

Seldom - fatigue, diarrhea.

Chloasma can sometimes develop, especially in women with a history of pregnant chloasma.

As with other combined oral contraceptives, in rare cases thrombosis and thromboembolism may occur.


Do not use Triquilar if you have any of the conditions or diseases listed below. If any of them are detected, tell your doctor.

  • Thrombosis (venous and arterial) and thromboembolism currently or in history, including: deep venous thrombosis, pulmonary embolism, myocardial infarction, cerebrovascular disorders.
  • The states preceding thrombosis (including transient ischemic attacks, angina pectoris) are currently or in history.
  • Migraine with focal neurological symptoms in history.
  • Diabetes with vascular complications.
  • Multiple or severe risk factors for venous or arterial thrombosis, including: cardiac valve system, cardiac arrhythmia, vascular diseases of the brain or coronary arteries, uncontrolled arterial hypertension.
  • Pancreatitis with severe hypertriglyceridemia now or in history.
  • Liver failure and severe liver disease (until liver tests return to normal).
  • Liver tumors (benign or malignant) currently or in history.
  • Identified hormone-dependent malignant diseases (including genitals or mammary glands) or suspicion of them.
  • Vaginal bleeding of unknown origin.
  • Pregnancy or suspicion of her.
  • Lactation period.
  • Hypersensitivity to any of the components of Triquilar.
  • Prolonged immobilization (for example, when a plaster bandage is applied to the leg), serious surgical intervention, surgery on the legs, extensive injuries.

If any of these conditions appear for the first time while receiving Triquilar, stop taking this drug right away and consult your doctor. In the meantime, use non-hormonal contraceptives.
Use with caution. If Triquilar is used in the presence of any of the conditions listed below, you may need careful observation - why, the doctor will explain. Before you start taking Triquilar, tell your doctor if you have any of the following conditions and diseases:

  • Smoking.
  • Diabetes.
  • Overweight.
  • High blood pressure.
  • Inflammation of the veins (phlebitis of the superficial veins).
  • Thrombosis, myocardial infarction or cerebrovascular accident in any of your closest relatives.
  • Migraine.
  • Acceptance of antiepileptic drugs.
  • High cholesterol or triglycerides (fatty acids) in you or any of your close relatives, now or in the past.
  • Breast cancer in any of your closest relatives.
  • Diseases of the liver or gallbladder.
  • Crohn's disease or ulcerative colitis.
  • Systemic lupus erythematosus (SLE).
  • Hemolytic uremic syndrome.
  • Sickle cell anemia.
  • Diseases that have first arisen or aggravated during pregnancy or against the background of a previous intake of sex hormones (for example, hearing loss, porphyria, herpes of pregnant women, Sydenhamma chorea).

Chloasma (yellowish - brown foci of pigmentation on the skin, especially on the face) now or in the past. If they are, avoid prolonged exposure to the sun or ultraviolet radiation.

Drug interactions

Some medicines can reduce the effectiveness of Triquilar. These include drugs used to treat epilepsy (for example, primidone, phenytoin, barbiturates, carbamazepine, oxcarbazepine, topiramate, felbamate), tuberculosis (for example, rifampicin, rifabutin) and HIV infection (ritonavir); antibiotics for the treatment of some other infectious diseases (for example, ampicillin, tetracyclines, griseofulvin), as well as hypericum medicines (used mainly in the treatment of depressive conditions). Sulfonamides, derivatives of pyrazolone are able to enhance the metabolism of the steroid hormones contained in the preparation.

Pregnancy and Lactation

Trikvilar can not be used during pregnancy and during lactation.

Special instructions

When skipping the drug Triquilar over 12 hours, you must take the next pill as quickly as possible and use additional methods of contraception until the end of the cycle. The effectiveness of the drug is reduced while taking drugs that activate the enzyme function of the liver, vomiting, diarrhea. Triquilar should be withdrawn during prolonged immobilization and 6 weeks before the planned surgical intervention.
It is not recommended to prescribe Triquilar to smokers over 35 years old. Women younger than 18 and older than 35-40 years are recommended three-phase low-dose drugs. For therapeutic and prophylactic purposes it is advisable to use monophasic drugs. The frequency and severity of side effects depends on the doses and ratios of the active substances that make up each preparation.


Symptoms that may occur during overdose: nausea, vomiting, bleeding from the genital tract.
In case of overdose, consult a doctor.

  • Brand name: Triquilar
  • Active ingredient: Ethinyl estradiol, Levonorgestrel
  • Dosage form: Dragee
  • Manufacturer: Bayer Pharma AG
  • Country of Origin: Germany

Studies and clinical trials of Ethinyl estradiol, Levonorgestrel (Click to expand)

  1. Modulation of ovarian function by an oral contraceptive containing 30 μg ethinyl estradiol in combination with 2.00 mg dienogest
  2. Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking
  3. Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables
  4. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse®)
  5. A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 μg levonorgestrel with 20 μg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol
  6. The effects on ovarian activity of a monophasic oral contraceptive with 100 μg levonorgestrel and 20 μg ethinyl estradiol
  7. Effects of low-dose monophasic levonorgestrel with ethinyl estradiol preparation on serum lipid levels: A twenty-four month clinical trial
  8. The effects of a low-dose monophasic preparation of levonorgestrel and ethinyl estradiol on coagulation and other hemostatic factors
  9. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol
  10. The effect of ethinyl estradiol 20 mcg and levonorgestrel 250 mcg on the pituitary-ovarian function during normal tablet-taking and when tablets are missed
  11. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel
  12. The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive
  13. A comparative study of the effects of a monophasic and a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism
  14. Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: A double-blind, placebo-controlled study
  15. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 μg ethinyl estradiol combined with 100 μg levonorgestrel
  16. Seasonale (30 μg of ethinyl estradiol/150 μg of levonorgestrel) extended-regimen oral contraceptive: efficacy and cycle control by body weight
  17. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results
  18. Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel 90 μg/ethinyl estradiol 20 μg
  19. Study of low-density lipoprotein receptor regulation by oral (steroid) contraceptives: desogestrel, levonorgestrel and ethinyl estradiol in JEG-3 cell line and placental tissue
  20. Effects of ethinyl estradiol and ibuprofen compared to placebo on endometrial bleeding, cervical mucus and the postcoital test in levonorgestrel subcutaneous implant users
  21. Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen
  22. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel
  23. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial
  24. Postmarketing study of ORTHO EVRA® and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism

8 other products in the same category: